Acute Lymphocytic Leukemia
Conditions
Keywords
Acute Lymphocytic Leukemia,, Ph+,, elderly patients,, Imatinib
Brief summary
ALL patients aged 55 years or older were treated with steroids during one week and Ph+ve cases were then offered a specific therapy including an induction treatment with steroids, cyclophosphamide, daunorubicin and vincristine, followed, irrespective of response to induction chemotherapy, by imatinib, 600 mg daily, combined with intermittent steroids during 2 months. Patients in complete response (CR) were then given 10 blocks of alternating chemotherapy, including 2 additional two-month blocks of imatinib, for a total treatment duration of 2 years. Therapy of occult central nervous system leukemia included 5 intrathecal injections of methotrexate and cranial irradiation. Duration of therapy : 2 years.
Interventions
DRUGimatinib
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Ph+ ALL patients * 55 years or older * Signed written informed consent
Exclusion criteria
* CML in transformation * Concomitant malignancy * Previous treatment by Imatinib * Severe organ condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Impact of Imatinib on survival in elderly patients with Ph+ALL | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete remission rate | — |
| Minimal Residual Disease after Imatinib treatment | — |
| Tolerance of Imatinib | — |
| Impact of steroids given before starting chemotherapy | — |
| Study of potential resistance mechanisums to Imatinib | — |
| Leukemia free survival | — |
Countries
France
Outcome results
None listed